Articles tagged with Lung Cancer
Researchers found that urban colorectal and lung cancer patients present at later stages of disease than their rural counterparts. This study highlights the need for improved screening efforts in both rural and urban populations to address disparities in cancer diagnosis.
Researchers found that computer-aided detection (CAD) combined with multi-detector computed tomography (MDCT) improves radiologists' ability to detect solid lung nodules. CAD successfully matched 91.3% of nodules detected in both exams, and reduced reading time for radiologists.
The study provides a comprehensive view of the altered genetic background of lung adenocarcinoma, revealing new insights into its biology. The identification of the NKX2-1 gene highlights the importance of understanding the molecular properties of tumors to develop effective cancer diagnosis and therapy strategies.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a novel mechanism to predict survival in older women with early-stage lung cancer. Higher levels of aromatase, an enzyme that produces estrogen, are associated with more aggressive disease and lower survival rates in women over 65.
A prospective study found that quality of life surpasses classic predictors like disease stage and tumor size in determining survival. Patients with better quality of life scores had a significantly higher rate of survival.
A study published in the Journal of the National Cancer Institute found that treatment with a vitamin A derivative called retinoic acid reduced the growth of lung cells in former heavy smokers. The researchers also found that the treatment slowed down cell growth in the parabasal layer of lung cells, but not in the basal layer.
Three studies investigate how tumors respond to EGFR inhibitors, revealing the crucial role of BIM protein in triggering apoptosis. The findings suggest that induction of BIM may lead to a new way of treating tumors resistant to these drugs.
Researchers found that PET scans at 3 months post-treatment can evaluate tumor response earlier and more accurately than current methods. Stereotactic body radiotherapy may be as effective as surgery in treating small tumors, but early detection is crucial to prevent treatment delays.
A new study published in CANCER found that despite significant increases in healthcare expenditures, survival rates for elderly patients with lung cancer remained relatively stable between 1983 and 1997. The average life-expectancy rose by less than one month, while costs increased by over $20,000 per patient.
Scientists identified DMP1 as a tumor suppressor that activates Arf expression, inducing p53-dependent cell cycle arrest. DMP1 deletion or haploid insufficiency accelerates lung cancer development in K-ras mutated mice and patients, suggesting its potential as a target for drug therapy.
Scientists have discovered a new gene, Dmp1, linked to human lung cancer, which is often deleted in lung tumors. The study found that the non-functional Dmp1 gene leads to reduced activity of tumor suppressors p53 and Arf, allowing cancer cells to grow unchecked.
The report found that cancer death rates declined by an average of 2.1 percent per year from 2002 to 2004, nearly twice the annual decrease of 1.1 percent per year from 1993 to 2002. Cancer incidence rates among American Indians and Alaska Natives varied two-fold across six geographic regions.
A study published in Thorax reveals a potential early warning system for lung cancer, detecting autoantibodies in blood that are associated with solid tumours and triggered by cancerous changes. The presence of these autoantibodies in patients indicates an 80% chance of a cure if the disease has not yet spread.
Researchers at CSHL have identified three genes causing 20% of lung cancers that interact to reactivate fetal gene expression patterns leading to tumor growth. Reversing these genes may lead to new treatment options for patients.
The NIBIB Quantum Grants program funds four innovative projects to develop new technologies for metastatic lung cancer diagnosis, bio-artificial kidneys, insulin-producing cells, and nanoparticles targeting brain tumors. These advancements aim to transform healthcare with potential breakthroughs in disease treatment and prevention.
A new study led by Duke University researchers found distinct differences in tumor susceptibility to chemotherapy drugs based on gene expression profiling. This allows clinicians to predict which patients are most likely to respond to standard therapy and offers alternative options for those not responding.
A study suggests that patients with non-squamous histology achieve statistically significant higher survival when treated with ALIMTA in the second-line setting compared to those with squamous histology. The analysis also identified other predictive factors for potential benefit from treatment, including adenocarcinoma histology and go...
A new blood test has been developed to detect lung cancer in its earliest stage, promising improved diagnosis and treatment options. The test targets the Human Aspartyl (Asparaginyl) ß-Hydroxylase protein, which is abnormally expressed on the surface of cancer cells.
Researchers have identified a panel of 15 genes that can serve as a biomarker for lung cancer, which may help identify individuals at high risk for the disease. The test, which analyzed gene activity in lung cells, showed a 96% accuracy rate in identifying lung cancer patients.
A third of prostate biopsies detected cancer, with the risk increasing with each subsequent biopsy. Gene variants influencing innate immunity also linked to improved or poorer lung cancer survival in white patients. Brain tumor stem cells susceptible to a cancer-killing virus, offering new treatment hope.
Research found knee monoarthritis in 296 patients (4.4%) with rheumatic disorders, a rare condition associated with operable non-small cell lung cancer. The disease is challenging to treat unless caught early, and the discovery provides new insights into potential early warning signs.
A common molecular pathway called retinoblastoma (RB) tumor suppressor could help predict which lung cancer patients will benefit from chemotherapy drugs. Researchers found that turning off the RB pathway resulted in an altered response to chemotherapy agents and more cancer cell death.
Researchers at UT Southwestern Medical Center have found that combining radiation therapy with the drug bavituximab significantly improves the effectiveness of lung cancer treatment. The drug targets tumor blood vessels by selectively binding to exposed phospholipids, signaling white blood cells to attack and destroy them.
Researchers developed a new technique that can detect specific chromosomal damage associated with lung cancer, which may indicate an increased risk. The study found significant differences in chromosomal abnormalities between never-smokers and high-risk smokers and patients with lung cancer.
Researchers identified genes that are irreversibly activated by smoking, leading to increased lung cancer risk in former smokers. The study's findings provide insight into why former smokers remain susceptible to lung cancer despite quitting.
Researchers found that taking vitamins and minerals did not reduce liver cancer death rates in a study conducted by the National Cancer Institute. However, some vitamin-mineral combinations reduced risk in subgroups defined by age, sex, and alcohol consumption. In contrast, gene expression patterns identified 11 genes in noncancerous l...
A nationwide survey found that nearly seven in ten Americans believe the risk of dying from cancer is increasing, despite clear evidence to the contrary. The study also revealed associations between sociodemographic variables, such as gender and education level, and the likelihood of believing false statements about cancer risks.
Researchers found a strong correlation between tumor responses during treatment and three months after completion, suggesting PET scans can be performed earlier to modify treatment plans. This could lead to better tumor control and survival rates, potentially changing standard practice guidelines.
Researchers have identified IL6 as a protein that stimulates tumor growth when activated by Ras, leading to increased blood vessel formation. Suppressing IL6 activity has shown promising results in fighting tumor formation in preclinical models.
Researchers found gene variations in interleukin 1A and 1B to be a major risk factor for lung cancer, particularly among heavy smokers. These variants can lead to an overzealous inflammatory response, causing genetic damage and cancer.
A recent study found that restaurant workers exposed to tobacco smoke have higher levels of NNK, a potent lung carcinogen. The researchers concluded that clean air exemptions are unjustified and policymakers should prohibit smoking in all indoor workplaces.
Cancer researcher Dimitrios Trichopoulos received a medal of honor from the World Health Organization's cancer agency for his work linking passive smoking to lung cancer. He has also explored the Mediterranean diet's role in reducing cancer and heart disease risk.
Researchers at UT Southwestern Medical Center have discovered how the compound beta-lapachone kills certain cancer cells, leading to a new paradigm for treating non-small cell lung cancer. Beta-lapachone interacts with an enzyme called NQO1, present in high levels in non-small cell lung cancer and other solid tumors.
Death rates from lung and bladder cancer remained high decades after residents in northern Chile were exposed to high levels of arsenic, indicating a clear pattern of latency in health effects. The study found that mortality risks continued to rise long after exposure ended, supporting the need for more testing of world's water sources.
A study found that arsenic exposure led to a significant rise in lung and bladder cancer deaths, with mortality rates peaking 10-20 years after exposure ended. The research suggests the need for controlling arsenic concentrations in drinking water worldwide.
Researchers found that talc stimulates healthy cells to produce endostatin, a hormone that inhibits tumor growth and kills tumor cells. The study reveals talcum powder's potential as a therapeutic agent for metastatic lung cancer, offering new hope for patients with incurable disease.
A multi-center team has discovered a 'signature' of proteins in the blood that predicts which non-small-cell lung cancer patients will live longer when treated with targeted therapies. The findings could help physicians decide which patients to treat with drugs known as EGF receptor tyrosine kinase inhibitors.
Research from Dana-Farber Cancer Institute reveals that Black Americans are less certain about lung cancer prevention recommendations and more fearful of symptoms evaluation, potentially delaying treatment. This fatalism may contribute to Black patients being diagnosed with advanced stages of the disease.
A new genomic test can identify specific patterns among thousands of genes to determine the precise pathways that led to lung cancer. Researchers found that tumors with defects in certain pathways responded well to targeted therapy, offering a potential alternative to traditional chemotherapy.
A study reveals that genetic differences in Japanese and US patients with non-small cell lung cancer affect how well they respond to chemotherapy drugs like paclitaxel and carboplatin. The research found that specific gene variations, such as CYP3A4 and ERCC2, influence treatment outcomes.
A Phase III study suggests ALIMTA-carboplatin may deliver less toxicity than GEMZAR-carboplatin, offering comparable quality-of-life benefits and survival data. The combination also appears to benefit from a lower toxicity profile.
A large Phase III study found that shark cartilage extract AE-941 has no benefit when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer. The study did not meet its primary endpoint: survival, and the researchers cast major skepticism on the efficacy of shark cartilage products.
A study of 519 patients found no benefit in overall survival from pre-operative chemotherapy for nonsmall cell lung cancer. Neo-adjuvant therapy did result in tumor down-staging and improved response rates, but its use should be targeted towards specific patient subgroups.
Two Lilly studies analyzed data from African-American and Hispanic patients with non-small cell lung cancer (NSCLC), suggesting race may not significantly impact treatment efficacy. The studies provided insight into the safety profiles of ALIMTA and GEMZAR in diverse populations, paving the way for further research.
A large observational study found that taking vitamin supplements does not decrease the risk of lung cancer. The study involved 77,738 men and women aged 50-76 and found no statistically significant relationships between supplements and lung cancer.
A large cohort study found that using Swedish moist snuff (snus) increases the risk of developing pancreatic cancer by twice the rate of non-users. The study, conducted on almost 300,000 male construction workers, suggests that while the risks are small, snus use can still be a concern for overall health.
Researchers at University of Texas M. D. Anderson Cancer Center developed a lung cancer risk assessment tool using standard clinical and epidemiological data. The model assigns a score assessing a person's risk for the disease, with a prediction level of about 60 percent.
Researchers have confirmed that tamoxifen prevents breast cancer in high-risk women, while a combination of three HER inhibitors slows down tumor growth. Additionally, chemotherapy with rituximab improves overall survival rates for patients with indolent lymphoma, and new lung cancer risk prediction models offer modest accuracy.
The study found that lung cancer cells can become resistant to novel targeted agents by undergoing a miniscule molecular change in the EGFR protein. Researchers developed compounds to overcome resistance with innovative combinations of medications, which showed promise in preventing further resistance.
Researchers found that East Asians have lower levels of the EGFR protein, but those with lung cancer tend to have increased levels. This could explain why East Asians respond better to a certain type of chemotherapy.
Researchers at the University of Texas M. D. Anderson Cancer Center have successfully delivered a cancer-suppressing gene into tumors of stage 4 lung cancer patients via an intravenously administered lipid nanoparticle. The gene, FUS1, was found to be active in metastatic non-small cell lung cancer tumors.
Researchers are developing gene therapies that can target and kill cancer cells, while also exploring the use of viruses and other natural systems to design new cancer treatments. Studies have shown promising results in animal models, including a novel gene therapy approach that eradicates aggressive prostate cancer.
Patients undergoing minimally invasive lung cancer surgery experience shorter hospital stays and accelerated recovery times compared to traditional open surgery. This approach also improves chemotherapy delivery, reducing delays and increasing treatment efficacy.
Researchers found that regular high-dose inhaled corticosteroid use among COPD patients lowered the risk of developing lung cancer. The study, published in the American Journal of Respiratory and Critical Care Medicine, found a significant reduction in relative risk for users of over 1,200 micrograms per day.
A lung cancer screening regimen has been found to identify patients with early-stage cancer, allowing for curative treatment. The study suggests that annual repeat screenings can detect lung cancer at its earliest stage, resulting in a high proportion of patients having no evidence of metastases.
A new study shows radiofrequency ablation effective for early-stage, inoperable lung cancer, achieving survival rates equal to or better than traditional external beam radiation. The treatment resulted in a 57% five-year survival rate and controlled tumor progression.
A recent study by Ohio State University researchers has identified a link between the absence of the Olig1 protein in lung tumors and poor survival rates among patients with non-small cell lung cancer. The findings suggest that patients with low levels of the protein may benefit from more aggressive therapy after surgery, potentially i...
According to a randomized controlled trial, radiation therapy is the preferred treatment option for patients with locally advanced stage IIIA-N2 non-small-cell lung cancer who have responded to chemotherapy. This finding suggests that surgery may not improve survival rates compared to radiation after chemotherapy treatment.
A blood pressure drug has shown potential as a new treatment for lung cancer, shrinking tumor volume by 30% in mice. The hormone angiotensin-(1-7) was found to reduce cyclooxygenase-2, an enzyme that regulates cell growth, and may provide a novel approach to treating the deadly disease.
Researchers studied two lung cancer-derived EGFR mutants and found distinct differences in inhibitor binding, leading to overactivation of the enzyme. The study suggests that specific mutants have unique targets for inhibition, potentially reducing toxicity and increasing effectiveness.